Improvement in patient-reported outcomes in 2 Phase 3 studies of tofacitinib in patients with moderately to severely active ulcerative colitis

被引：0
|
作者：
Panes, J. [1 ]
Su, C. [2 ]
Marren, A. [2 ]
Yu, D. [2 ]
Woodworth, D. [2 ]
Zhang, H. [2 ]
Healey, P. [3 ]
机构：
[1] Hosp Clin Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
[2] Pfizer Inc, Collegeville, PA 19426 USA
[3] Pfizer Inc, Groton, CT 06340 USA
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P369
引用
收藏
页码：S283 / S284
页数：2
相关论文
共 50 条
  • [1] Improvement in Patient-Reported Outcomes in Two Phase 3 Induction Studies of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis
    Panes, Julian
    Su, Chinyu
    Marren, Amy
    Yu, Dahong
    Woodworth, Deborah A.
    Zhang, Haiying
    Healey, Paul J.
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S1003 - S1003
  • [2] PREDICTIVE VALUE OF PATIENT-REPORTED OUTCOMES TO MUCOSAL HEALING IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Colombel, J. F.
    Han, C.
    Reinisch, W.
    Feagan, B.
    Marano, C.
    Strauss, R.
    Johanns, J.
    Zhang, H.
    Gibson, P.
    Collins, J.
    Rutgeerts, P.
    Sandborn, W.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A40 - A40
  • [3] MAINTENANCE OF QUALITY OF LIFE IMPROVEMENT IN A PHASE 3 STUDY OF TOFACITINIB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Panes, Julian
    Rubin, David T.
    Vermeire, Severine
    Lindsay, James O.
    Sands, Bruce E.
    Su, Chinyu
    Friedman, Gary
    Zhang, Haiying
    Kayhan, Cem
    Manuchehri, Alireza
    Healey, Paul J.
    [J]. GASTROENTEROLOGY, 2017, 152 (05) : S601 - S602
  • [4] MAINTENANCE OF QUALITY OF LIFE IMPROVEMENT IN A PHASE 3 STUDY OF TOFACITINIB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Panes, J.
    Rubin, D. T.
    Vermeire, S.
    Lindsay, J. O.
    Sands, B. E.
    Su, C.
    Friedman, G.
    Zhang, H.
    Kayhan, C.
    Manuchehri, A.
    Healey, P.
    [J]. GUT, 2017, 66 : A121 - A122
  • [5] Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis
    Panes, J.
    Rubin, D. T.
    Vermeire, S.
    Lindsay, J. O.
    Sands, B. E.
    [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S315 - S317
  • [6] Tofacitinib in active ulcerative colitis: Analysis of efficacy based on patient-reported outcomes
    Panes, J.
    Su, C.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Mamolo, C.
    Healey, P.
    [J]. JOURNAL OF CROHNS & COLITIS, 2014, 8 : S51 - S51
  • [7] Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
    Panes, Julian
    Su, Chinyu
    Bushmakin, Andrew G.
    Cappelleri, Joseph C.
    Mamolo, Carla
    Healey, Paul
    [J]. BMC GASTROENTEROLOGY, 2015, 15
  • [8] Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
    Julián Panés
    Chinyu Su
    Andrew G Bushmakin
    Joseph C Cappelleri
    Carla Mamolo
    Paul Healey
    [J]. BMC Gastroenterology, 15
  • [9] Effect of Tofacitinib on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis: Results from 2 Phase 3 Studies
    Strand, Vibeke
    de Vlam, Kurt
    Covarrubias-Cobos, Jose A.
    Mease, Philip J.
    Gladman, Dafna D.
    Hendrikx, Thijs
    Kudlacz, Elizabeth
    Graham, Daniela
    Wu, Joseph
    Cappelleri, Joseph C.
    Hsu, Ming-Ann
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [10] Patient-Reported Outcome Improvement with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program
    Hudesman, David
    Torres, Joana
    Salese, Leonardo
    Woolcott, John C.
    Mundayat, Rajiv
    Su, Chinyu
    Mosli, Mahmoud H.
    Allegretti, Jessica R.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S403 - S404
12345